报价延迟最少15分钟:2025/07/20 16:51 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
65.13 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.49/-3.28
|
|
企业价值
4.96B
|
| 资产负债 |
|
每股账面净值
21.18
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
35.00M
|
|
每股收益
1.97
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 16:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
